Influence of the cytochrome P4502D6*4 allele on the pharmacokinetics of controlled-release metoprolol

European Journal of Clinical Pharmacology

Volumn 54, Issue 6, 1998, Pages 469-474

  Koytchev, R ^a   Alken, R G ^a   Vlahov, V ^b   Kirkov, V ^b   Kaneva, R ^c   Thyroff Friesinger, U ^d   Rehak, E ^d  

^a Co Oper Clin Drug R and D ^*  (Germany)

^b UNIVERSITY HOSPITAL 'QUEEN GIOVANNA'   (Bulgaria)

^c UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^d Sandoz Biopharmaceuticals   (Germany)

Author keywords

CYP2D6; Genetic polymorphism; Human; Metoprolol; Pharmacokinetics

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; METOHEXAL; METOPROLOL TARTRATE; UNCLASSIFIED DRUG;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG HALF LIFE; ENZYME ACTIVITY; FLUORESCENCE; GENETIC POLYMORPHISM; GENOTYPE; HEART RATE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOSITY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; MEAN RESIDENCE TIME; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION; TECHNIQUE;

ADRENERGIC BETA-ANTAGONISTS; ALLELES; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2D6; DELAYED-ACTION PREPARATIONS; HETEROZYGOTE; HOMOZYGOTE; HUMANS; MALE; METOPROLOL; POLYMERASE CHAIN REACTION; REFERENCE VALUES;

EID: 0031660591     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050495     Document Type: Article

References (25)

1. Agúndez JAG, Martinez C, Ledesma MC, Ladona MG, Ladero JM, Benitez J (1994) Genetic basis for differences in debrisoquin polymorphism between a Spanish and other white populations. Clin Pharmacol Ther 55: 412-417
2. Al-Hadidi HF, Irshaid YM, Rawashdeh NM (1994) Metoprolol α-hydroxylation is a poor probe for debrisoquine oxidation (CYP2D6) polymorphism in Jordanians. Eur J Clin Pharmacol 47: 311-314
3. Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphism of debrisoquine and mephenytoin in a European population. Eur J Clin Pharmacol 39: 533-537
4. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Lia X-M et al (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylation of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 51: 388-397
5. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 8: 545-558
6. Brosen K, Gram LF (1989) Clinical significance of the sparteine/ debrisoquine polymorphism. Eur J Clin Pharmacol 36: 537-547
7. Cholerton S, Daly AK, Idle JR (1992) The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 13: 434-439
8. Dahl ML, Johanson I, Palmertz MP, Ingelman-Sundberg M, Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51: 12-17
9. Daly AK, Armastrong M, Monkman SC, Idle ME, Idle JR (1991) Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1: 33-41
10. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6: 193-201
11. Eichelbaum M, Bertilsson L, Saewe J, Zekorn C (1982) Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clin Pharmacol Ther 31: 184-186
12. Evans WE, Relling MW, Rahman A, McLeod H, Seott E, Lin JS (1993) Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans. J Clin Invest 91: 2150-2154
13. Evans DAP, Mahgoub A. Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquin oxidation in a white British population. J Med Genet 17: 102-105
14. Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532
15. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterisation of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46: 452-459
16. Lennard MS, Silas JH (1983) Rapid determination of metoprolol and α-hydroxymetoprolol in human plasma and urine by high-performance liquid chromatography. J Chromatogr 272: 205-209
17. Lennard MS (1985) Quantitative analysis of metoprolol and three of its metabolites in urine and liver microsomes by high-performance liquid chromatography. J Chromatogr 342: 199-205
18. Mahgoub A, Dring LG, Idle JR, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584-586
19. Masimirembwa C, Hasler J, Bertilssons L, Johansson, Ekberg O, Ingelman-Sundberg M (1996) Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. Eur J Clin Pharmacol 51: 117-122
20. McGourty JC, Silas JH, Lennard MS, Tucker GT, Woods HF (1985) Metoprolol metabolism and debrisoquine oxidation polymorphism population and family studies. Br J Clin Pharmacol 20: 555-566
21. Nakamura K, Goto F, Ray WA, McAlister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian Populations. Clin Pharmacol Ther 38: 402-408
22. Nietzel HA (1986) A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 73: 320-332
23. Porter TD, Coon MJ (1991) Cytochrome P450: multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. J Biol Chem 266: 13469-13472
24. Rutledge DR, Garrick C (1989) Rapid high-performance liquid chromatographic method for the measurement of the enantiomers of metoprolol in serum using a chiral stationary phase. J Chromatogr 497: 181-190
25. Smith DA, Jones BC (1992) Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 44: 2089-2098